Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | GCGR | P47871 | 1/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ILK | Q13418 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3655297 | 0.81 | PIK3CD (0.57) | MAPK14MAPK1NPSR1CYP3A4ILK | |
| SCHEMBL5454847 | 0.80 | CDC7 (0.49) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL1013845 | 0.80 | CYP3A4 (0.61) | MAPK14MAPK1NPSR1MAPK13MAPK12 | |
| SCHEMBL1017069 | 0.79 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL6132051 | 0.78 | MAPK1 (0.83) | MAPK14MAPK1NPSR1CYP3A4ILK | |
| SCHEMBL8036864 | 0.77 | NR1H2 (0.51) | CYP3A4NR1H2NR1H3KDM4EKMT2A | |
| SCHEMBL3653300 | 0.77 | MAPK14 (0.54) | MAPK14MAPK1NPSR1MAPK13MAPK12 | |
| SCHEMBL1459110 | 0.75 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL8382254 | 0.75 | NPC1 (0.62) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL3514911 | 0.73 | NR1H2 (0.50) | MAPK1CYP3A4NR1H2NR1H3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102083835-A | Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-A]pyrimidines, methods for preparation and uses thereof | WYETH CORP | 2011-06-01 | — | — | CN | disclosed |
| EP-2271649-A1 | BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | Wyeth LLC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2203453-A1 | PYRAZOLO[5, 1-C] [1,2,4]TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009111260-A1 | PHENYLSULFONAMIDE-SUBSTITUTED, PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009108838-A1 | BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009039387-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | WYETH (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082354-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082354-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082354-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082354-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | RAF1, BRAF, ARAF | MAPK14 242/4885MAPK1 47/4885NPSR1 2187/4885 |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | BRAF, RAF1, ARAF | MAPK14 70/4885MAPK1 34/4885NPSR1 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.